Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.60 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.60 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.60 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29727825 | 1.00 | HTR2B (1.00) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL9391684 | 0.99 | HTR2B (0.98) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL29462336 | 0.99 | HTR2B (0.98) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL11043054 | 0.99 | HTR2B (0.98) | HTR2BCHRM4DRD2HTR7HTR2A | |
| Hydrochloric Acid SCHEMBL8197416 | 0.92 | HTR2B (0.85) | HTR2BCHRM4DRD2HTR7HTR2A | |
| Hydrochloric Acid SCHEMBL7817705 | 0.92 | HTR2B (0.85) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL7816407 | 0.91 | HTR2B (0.83) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL8659369 | 0.91 | HTR2B (0.83) | HTR2BCHRM4DRD2HTR7HTR2A | |
| SCHEMBL7808480 | 0.90 | HTR2B (0.82) | HTR2BCHRM4DRD2HTR7HTR2A | |
| Hydrochloric Acid SCHEMBL8399508 | 0.90 | HTR2B (0.81) | HTR2BCHRM4DRD2HTR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | claimed |
| US-20180325909-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2018-11-15 | — | — | US | claimed |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-03-16 | — | — | US | claimed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20180325909-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2018-11-15 | — | — | US | disclosed |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| EP-0749313-A4 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6090945-A | HIGH AFFINITY FOR THE 5-HT1C RECEPTOR. | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0797994-A2 | Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings | ELI LILLY AND COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5635528-A | RECEPTOR BINDING MODULATORS, FOR CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0749313-A1 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR2B 1/4885CHRM4 356/4885DRD2 138/4885 |
| US-20180325909-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR2B 1/4885CHRM4 356/4885DRD2 138/4885 |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR2B 1/4885CHRM4 356/4885DRD2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.